MOZAVAPTAN

Details

Stereochemistry	RACEMIC
Molecular Formula	C27H29N3O2
Molecular Weight	427.5381
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4

InChI

InChIKey=WRNXUQJJCIZICJ-UHFFFAOYSA-N

InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)

HIDE SMILES / InChI

Molecular Formula	C27H29N3O2
Molecular Weight	427.5381
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/818f4654ed39a1c147d1e51a00ffb4cb.html
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800001739 http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33180

Mozavaptan hydrochloride was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 26, 2006. It was developed and marketed as Physuline® by Otsuka in Japan. Mozavaptan hydrochloride is a vasopressin receptor antagonist. It is indicated for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Physuline® is available as film-coated tablet for oral use, containing 30 mg of Mozavaptan hydrochloride. The recommended dose is one tablet (30 mg) once daily after a meal.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vasopressin V1 receptor 2 Target ID: CHEMBL2111456 Sources: http://www.selleckchem.com/products/mozavaptan.html	Antagonist 2778		1.2 µM [IC50]
Vasopressin V2 receptor 15 Target ID: CHEMBL1790 Sources: http://adisinsight.springer.com/drugs/800001739	Antagonist 2778		14.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyponatremia 4 Sources: http://adisinsight.springer.com/drugs/800001739	Primary		Approved 8429	PHYSULINE Approved Use PHYSULINE is used for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Launch Date 2006

PubMed

Title	Date	PubMed
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.	1992 Apr	1387020
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.	1997 Oct	9322919
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.	1998 Dec	9884074
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.	1998 Dec	9864265
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.	1998 Nov 6	9792651
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.	2000 Oct	11012895
Vasopressin V(1) receptor-mediated activation of central sympatho-adrenomedullary outflow in rats.	2002 Dec 13	12460640
Gateways to clinical trials.	2003 Jun	12851663
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze.	2003 Mar	12646291
Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.	2008	18655905
Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.	2008 Mar	18288441
[Vasopressin receptor antagonists: the vaptans].	2010 May	21130961

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is one tablet (30 mg) once daily after a meal.

Route of Administration: Oral

In Vitro Use Guide

Mozavaptan caused a concentration-dependent displacement of the selective AVP V2 receptor antagonist radioligand, [3H]desGly-NH2(9)[d(CH2)5, D-Ile2,Ile4]AVP from V2 receptors in rat kidney medulla membranes. The concentration of Mozavaptan that displaced 50% of specific AVP binding (IC50) was 20 +/- 2 nmol/l for renal V2 receptors.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:15:51 GMT 2023` Edited by `admin` on `Fri Dec 15 16:15:51 GMT 2023`
Record UNII	17OJ42922Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOZAVAPTAN

Official Name

English

mozavaptan [INN]

Common Name

English

N-(4-(((5RS)-5-(DIMETHYLAMINO)-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)CARBONYL)PHENYL)-2-METHYLBENZAMIDE

Systematic Name

English

Mozavaptan [WHO-DD]

Common Name

English

MOZAVAPTAN [MI]

Common Name

English

MOZAVAPTAN [MART.]

Common Name

English

MOZAVAPTANE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2180